Neurological Sciences

, Volume 29, Supplement 5, pp 375–376 | Cite as

Dopamine agonists and therapy compliance



Dopamine replacement therapy in Parkinson’s disease improves motor symptoms, however some patients suffer from motor and behavioural disturbances attributable to taking doses of medication well beyond the dose required to treat their motor disabilities. Dopamine dysregulation syndrome (DDS) can be regarded as a pattern of compulsive medication use, leading to disabling motor and behavioural features. DDS, probably attributed to pulsatile overstimulation of the limbic dopaminergic system, is characterised by severe dopamine addiction and behavioural disorders such as pathological gambling (PG), hypersexuality, punding and mood swings. PG is a form of impulse control disorder (ICD), consisting of persistent and maladaptive gambling of various types, which affects personal, family and occupational activity. The treatment of the syndrome is difficult, hence a strict adherence to antiparkinson medication should be encouraged for prevention.


L-DOPA Dopamine dysregulation syndrome Pathologic gambling Therapy compliance 


  1. 1.
    Giovannoni G, O’sullivan JD, Turner K et al (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68:423–428PubMedCrossRefGoogle Scholar
  2. 2.
    Molina JA, Sáinz-Artiga MJ, Fraile A et al (2000) Pathologic gambling in Parkinson’s disease: a behavioural manifestation of pharmacologic treatment? Mov Disord 15:869–872PubMedCrossRefGoogle Scholar
  3. 3.
    Avanzi M, Baratti M, Cabrini S et al (2006) Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 21:2068–2072PubMedCrossRefGoogle Scholar
  4. 4.
    Voon V, Hassan K, Zurowski M et al (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66:1750–1752PubMedCrossRefGoogle Scholar
  5. 5.
    Grosset KA, Bone I, Grosset DG et al (2005) Suboptimal medication adherence in Parkinson’s disease. Mov Disord 20:1502–1507PubMedCrossRefGoogle Scholar
  6. 6.
    Grosset DG, Grosset KA (2006) Measuring therapy adherence in Parkinson’s disease: a comparison of methods. J Neurol Neurosurg Psychiatry 77:249–251PubMedCrossRefGoogle Scholar
  7. 7.
    Grosset DG, Grosset KA (2007) Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol 7:20PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Institute of Neurological Sciences Department of NeurologySouthern General HospitalGlasgowUK

Personalised recommendations